Role of protease-activated receptor-1 (PAR-1) in the glomerular filtration barrier integrity

被引:4
|
作者
Medipally, Ajay [1 ]
Xiao, Min [1 ]
Biederman, Laura [1 ]
Satoskar, Anjali A. [1 ]
Ivanov, Iouri [1 ]
Rovin, Brad [2 ]
Parikh, Samir [2 ]
Kerlin, Bryce A. [3 ,4 ]
Brodsky, Sergey, V [1 ]
机构
[1] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Med, Wexner Med Ctr, Columbus, OH 43210 USA
[3] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA
[4] Nationwide Childrens Hosp, Ctr Clin & Translat Res, Abigail Wexner Res Inst, Columbus, OH USA
来源
PHYSIOLOGICAL REPORTS | 2022年 / 10卷 / 15期
关键词
anticoagulant related nephropathy; glomerular filtration barrier; PAR-1; renal pathology; ACUTE KIDNEY INJURY; WARFARIN; NEPHROPATHY; COAGULATION; PROTECTION; MODEL;
D O I
10.14814/phy2.15343
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Protease-activated receptors (PAR) play an important role in the regulation of cellular function by the coagulation system, and they are activated by thrombin. PAR-1 is expressed in both endothelial cells and podocytes in the kidney. The role of PAR1 in the maintenance of the glomerular filtration barrier is not clear. Anticoagulant-related nephropathy (ARN) is a kidney disease with glomerular hematuria and red blood cell tubular casts. We validated 5/6 nephrectomy (5/6NE) in rats as a model of ARN and had demonstrated that direct thrombin inhibitor (dabigatran) induces ARN. The aim of this study was to investigate the role of PAR-1 in the ARN pathogenesis. 5/6NE rats were treated with dabigatran (150 mg/kg/day), PAR-1 inhibitor SCH79797 (1 and 3 mg/kg/day) and PAR-1 agonist TFLLR-NH2 (0.25 and 0.50 mu mol/kg/day) for 7 days. Serum creatinine and hematuria were assessed daily. Kidney morphology was evaluated at the end of the study. In 5/6NE rats treated with either dabigatran or combination with a PAR-1 modulator, there was an elevation in serum creatinine, glomerular hematuria, red blood casts in the tubules, and acute tubular epithelial cell injury. Interestingly, both PAR-1 modulators in a dose-depended manner had similar effects on the serum creatinine levels and hematuria as those of dabigatran. Dabigatran-induced increase in the systolic blood pressure was not affected by PAR-1 modulators. In conclusion, the normal function of PAR-1 is crucial to maintain the glomerular filtration barrier integrity. Either activation or blockage of PAR-1 leads to glomerular hematuria and subsequent acute tubular epithelial cell injury.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] The Effect of Protease-Activated Receptor-1 (PAR-1) Inhibition on Endothelial-Related Biomarkers in Patients with Coronary Artery Disease
    Nilsen, Dennis W. T.
    Roysland, Michelle
    Ueland, Thor
    Aukrust, Pal
    Michelsen, Annika E.
    Staines, Harry
    Barvik, Stale
    Kontny, Frederic
    Nordrehaug, Jan Erik
    Bonarjee, Vernon V. S.
    [J]. THROMBOSIS AND HAEMOSTASIS, 2023, 123 (05) : 510 - 521
  • [32] IN VIVO PROTEASE-ACTIVATED RECEPTOR-1 MEDIATED CORONARY VASOREACTIVITY CORRELATES WITH PAR-1 EXPRESSION DISTRIBUTION IN THE CORONARY VASCULAR WALL
    Kasasbeh, E. S.
    Phillips, S. A.
    Couhtino, L.
    Williams, P.
    Nunnally, A. H.
    Adcock, J.
    Wang, L.
    Hamm, H. E.
    Cleator, J. H.
    [J]. CARDIOLOGY, 2015, 131 : 285 - 285
  • [33] Expression of protease-activated receptor-1 (PAR-1): A differential marker for metastasis of squamous cell carcinoma of the head and neck (SCCHN)
    Zhang, X
    Hunt, JL
    Landsittel, DP
    Shin, DM
    Chen, ZG
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1309S - 1309S
  • [34] Role of sorting nexins in protease-activated receptor-1 trafficking
    Garrett, TA
    Trejo, J
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2002, 13 : 134A - 135A
  • [35] Protease-Activated Receptor 1 (PAR-1) Antagonists as Potential Treatment for Acute Coronary Syndrome
    Abdel-Magid, Ahmed F.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (10): : 881 - 883
  • [36] Autoimmune Targeting of Protease Activated Receptor-1 (PAR-1) Deregulates VEGF and Disturbs Neoangiogenesis
    Catar, R.
    Schramm, I.
    Simon, M.
    Wischnewski, O.
    Philippe, A.
    Kusch, A.
    Dragun, D.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 382 - 382
  • [37] AUTOIMMUNE TARGETING OF PROTEASE ACTIVATED RECEPTOR-1 (PAR-1) DEREGULATES VEGF AND DISTURBS NEOANGIOGENESIS
    Schramm, I.
    Catar, R.
    Simon, M.
    Wischnewski, O.
    Philippe, A.
    Kusch, A.
    Dragun, D.
    [J]. TRANSPLANT INTERNATIONAL, 2013, 26 : 24 - 24
  • [38] Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependant on clopidogrel response
    Kreutz, Rolf P.
    Breall, Jeffrey A.
    Kreutz, Yvonne
    Owens, Janelle
    Lu, Deshun
    Bolad, Islam
    von der Lohe, Elisabeth
    Sinha, Anjan
    Flockhart, David A.
    [J]. THROMBOSIS RESEARCH, 2012, 130 (02) : 198 - 202
  • [39] Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response
    Kreutz, Rolf P.
    Flockhart, David A.
    Kreutz, Yvonne
    Breall, Jeffrey A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 58 (20) : B44 - B44
  • [40] Effect of Protease-Activated Receptor-1 (PAR-1) Activating Peptide in Murine Model of Endotoxin-Induced Lung Injury.
    Tanaka, R.
    Goto, E.
    Tsumura, S.
    Kojima, K.
    Saeki, S.
    Ito, K.
    Saita, N.
    Kohrogi, H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179